Neoadjuvant concurrent chemoradiotherapy followed by transanal total mesorectal excision assisted by single-port laparoscopic surgery for low-lying rectal adenocarcinoma: a single center study

Table 1 Characteristics of patients with middle to lower third rectal adenocarcinoma, receiving neoadjuvant concurrent chemoradiotherapy followed by trans-anal total mesorectal excision assisted by single port laparoscopic surgery

	n (%)
Sex
Male	13 (56.52)
Female	10 (43.48)
Age, median (range)	63 (31-80)
BMI (kg/m²), median (range)	23.7 (18-32)
ASA
ASA score 1	1 (4.35)
ASA score 2	19 (82.61)
ASA score 3	3 (13.04)
Distance to anal verge (mm), median (range)	54 (20-80)
Tumor size (mm), median (range)	20 (6-85)
AJCC clinical stages
Stage II	8 (34.78)
Stage III	15 (65.22)
Clinical T stage
cT2	2 (8.70)
cT3	21 (91.30)
Clinical N stage
cN0	8 (34.78)
cN1	11 (47.83)
cN2	4 (17.39)
Neoadjuvant CCRT	23 (100.00)

ASA American Society of Anesthesiologists, BMI body mass index, CCRT concurrent chemoradiotherapy, AJCC the American Joint Committee on Cancer

ISSN: 1477-7819